TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37535419

Group type: EXPERIMENTAL
Intervention: 3 mg of melatonin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg of melatonin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Personalized trial approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment measures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adherence measures
Number of subjects: 60
Study: 37535521

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ABC-I)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 149
Study: 37535555

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT) ROC-T
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) ROC-T
Number of subjects: 92

Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 92
Study: 37535575

Group type: EXPERIMENTAL
Intervention: DAIVE (decision analysis for intervention value efficiency)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAIVE
Number of subjects: 0
Study: 37535580

Group type: EXPERIMENTAL
Intervention: High levels of grief symptoms at 2 months postloss
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: PGD, PTSD, and depression
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Younger age and losing a spouse
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Between-person differences
Number of subjects: 1224
Study: 37535618

Group type: COMPARATOR
Intervention: Propofol (P group)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Remimazolam tosylate (RT group)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Remimazolam tosylate plus propofol (R+P group)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Co-administration of remimazolam tosylate and propofol (R+P group)
Number of subjects: 304
Study: 37535624

Group type: EXPERIMENTAL
Intervention: Functional exercise program (group I, 20 participants)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Posture exercise program (group II, 20 participants)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Functional exercise program (group I)
Number of subjects: 40
Study: 37535693

Group type: EXPERIMENTAL
Intervention: PPKAY (Brief Negotiational Interview)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PPKAY with standard text booster
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PPKAY with personalized text booster
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 75
Study: 37535695

Group type: EXPERIMENTAL
Intervention: O. volvulus positive epilepsy/nodding syndrome patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: O. volvulus positive nodding syndrome patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: O. volvulus negative individuals
Number of subjects: 0
Study: 37535775

Group type: EXPERIMENTAL
Intervention: Ozone injection
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency application
Number of subjects: 45

Group type: COMPARATOR
Intervention: All interventions (Ozone, Steroid, Pulsed Radiofrequency)
Number of subjects: 45
Study: 37535876

Group type: EXPERIMENTAL
Intervention: mFOLFOX + PAN
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 5-FU + LV + PAN
Number of subjects: 183
Study: 37535937

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 37535953

Group type: COMPARATOR
Intervention: Group 1 (no HBV treatment)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group 2 (single HBV treatment)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group 3 (dual HBV treatment)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 3
Study: 37536444

Group type: EXPERIMENTAL
Intervention: Bronchodilator response (BDR) defined by four different definitions, assessed using albuterol.
Number of subjects: 931
Study: 37536633

Group type: EXPERIMENTAL
Intervention: Through-the-scope helix tack suture system (TTSS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Over-the-scope suturing system (OTSS)
Number of subjects: 40
Study: 37536635

Group type: EXPERIMENTAL
Intervention: AI-assisted novice group (AN)
Number of subjects: 685
Study: 37536671

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD (S-ICD)
Number of subjects: 628
Study: 37536680

Group type: EXPERIMENTAL
Intervention: Choose to Move (CTM) virtual intervention
Number of subjects: 153
Study: 37536752

Group type: COMPARATOR
Intervention: 2019 (Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: 2020 (Pandemic)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Immunosuppression status
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Intensive care unit
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Visits from relatives
Number of subjects: 430
Study: 37536753

Group type: EXPERIMENTAL
Intervention: Physician-assisted suicide
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Euthanasia
Number of subjects: 331

Group type: COMPARATOR
Intervention: Cultural factors
Number of subjects: 331

Group type: COMPARATOR
Intervention: Belief in God
Number of subjects: 331
Study: 37536931

Group type: EXPERIMENTAL
Intervention: Calcification present
Number of subjects: 39

Group type: COMPARATOR
Intervention: No calcification
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Macrocalcification
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Spotty calcification
Number of subjects: 39
Study: 37536936

Group type: EXPERIMENTAL
Intervention: TLPLDC (n=103)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: TLPLDC+G (n=56)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: TLPO (n=43)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 187
Study: 37536941

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks for a total of 17 doses) and ipilimumab (1 mg/kg every 6 weeks for a total of 6 doses) starting 2 weeks prior to radiotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 24
Study: 37536965

Group type: EXPERIMENTAL
Intervention: PBP e-learning (group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: HSE course (group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Self-directed e-learning (S) (group 3)
Number of subjects: 120
Study: 37537219

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg daily)
Number of subjects: 47
Study: 37537324

Group type: EXPERIMENTAL
Intervention: Vie Scope
Number of subjects: 58

Group type: COMPARATOR
Intervention: Macintosh videolaryngoscopy (C-MAC®)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 37537541

Group type: EXPERIMENTAL
Intervention: Involved site irradiation (ISI)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Elective region irradiation (ERI)
Number of subjects: 414
Study: 37537548

Group type: EXPERIMENTAL
Intervention: Two distinct approaches to involving parents in adolescent obesity treatment
Number of subjects: 210
Study: 37537563

Group type: EXPERIMENTAL
Intervention: Day surgery (DS) for varicose veins with SVT below knee
Number of subjects: 593

Group type: COMPARATOR
Intervention: Day surgery (DS) for varicose veins without SVT
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Both groups (SVT and VV only)
Number of subjects: 593
Study: 37537576

Group type: EXPERIMENTAL
Intervention: Lipidomic Risk (LR) score based on 15 lipid species identified by Random Survival Forest (RSF)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Higher LR Score values
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Combined clinical variables and selected lipidic isomers
Number of subjects: 462
Study: 37537580

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Low-molecular weight heparin (LMWH) alone
Number of subjects: 1867

Group type: COMPARATOR
Intervention: LMWH and aspirin
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 1867
Study: 37537847

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for the upper limb (arm ergometer exercises)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for the lower limb (cycling)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as group A)
Number of subjects: 48
Study: 37537894

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) intervention via telerehabilitation (TR) method for 12 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cognitive rehabilitation (CR) intervention via face-to-face method for 12 weeks
Number of subjects: 68
Study: 37537928

Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 37538173

Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brensocatib (QD dosing)
Number of subjects: 0
Study: 37538332

Group type: EXPERIMENTAL
Intervention: Indoor daylight PDT (30 min of 5-aminolevulinic acid (ALA) pre-incubation, followed by 2 h of indoor sunlight)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lamp-based PDT (30 min of ALA pre-incubation, followed by 10 min of red light)
Number of subjects: 41
Study: 37538505

Group type: EXPERIMENTAL
Intervention: octocog alfa
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa
Number of subjects: 13
Study: 37538539

Group type: EXPERIMENTAL
Intervention: 3 doses of 125 μg subcutaneous pegylated IFNβ-1a
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1172
Study: 37538951

Group type: EXPERIMENTAL
Intervention: Colistin monotherapy (5 mg/kg once followed by 1.67 mg/kg every 8 hours)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Colistin in combination with meropenem (1000 mg every 8 hours)
Number of subjects: 423
Study: 37539061

Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) for 28 days
Number of subjects: 399
Study: 37539698

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 276
Study: 37539981

Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec (1.33 × 10^14 vg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec
Number of subjects: 20
Study: 37540036

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) added to furosemide, eGFR-adjusted doses
Number of subjects: 230

Group type: COMPARATOR
Intervention: Furosemide alone (control)
Number of subjects: 230
Study: 37540060

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 37540159

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) combined with glucocorticoids (GCs) and MTX
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tocilizumab (TCZ) combined with glucocorticoids (GCs) and MTX
Number of subjects: 40
Study: 37540206

Group type: EXPERIMENTAL
Intervention: FIL200
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: FIL100
Number of subjects: 86
Study: 37540289

Group type: EXPERIMENTAL
Intervention: Reduced miR-195
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Increased miR-10b
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Increased miR-145
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Decreased miR-21
Number of subjects: 101
Study: 37540312

Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (C-tDCS)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cerebello-spinal cathodal transcranial direct current stimulation (CS-tDCS)
Number of subjects: 7
Study: 37540323

Group type: EXPERIMENTAL
Intervention: Residual volume (RV)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Half of the maximum volume (MV)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Unchanged volume (NV)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 210
Study: 37540383

Group type: EXPERIMENTAL
Intervention: Prolotherapy with 10% dextrose concentration (Group 2)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Prolotherapy with 20% dextrose concentration (Group 3)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Prolotherapy with 5% dextrose concentration (Group 1)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Home exercise program (Group 4)
Number of subjects: 128
Study: 37540556

Group type: EXPERIMENTAL
Intervention: Antiangiogenic therapy (bevacizumab ± irinotecan, cabozantinib)
Number of subjects: 350
Study: 37540566

Group type: EXPERIMENTAL
Intervention: One or two infusions of third-generation CD19-directed CAR-Ts (2 × 10^8/m2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Effector-like CD8+CAR-Ts with a high polyfunctionality, high cytotoxic and cytokine production profile, and low dysfunctional signature
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extended ex vivo expansion time during CAR-T manufacturing
Number of subjects: 24
Study: 37540593

Group type: EXPERIMENTAL
Intervention: Thyroid hormones (TSH, T3, T4) and sex hormones (PRL, total testosterone) measured preoperatively and at 24 h postoperatively
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ICU hours, mechanical ventilation, and Vasoactive-Inotropic Score (VIS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ICU hours
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Postoperative and delta testosterone levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Model for End-Stage Liver Disease (MELD) scores
Number of subjects: 49
Study: 37540649

Group type: EXPERIMENTAL
Intervention: Index HIV self-testing (HIVST) with HIVST kits and instructions
Number of subjects: 484

Group type: COMPARATOR
Intervention: Standard partner referral slip (PRS)
Number of subjects: 484
Study: 37540692

Group type: EXPERIMENTAL
Intervention: 40 Hz tACS
Number of subjects: 0

Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 37540921

Group type: EXPERIMENTAL
Intervention: CCRT plus TIL infusion (n = 78)
Number of subjects: 156

Group type: COMPARATOR
Intervention: CCRT alone (n = 78)
Number of subjects: 156
Study: 37541047

Group type: EXPERIMENTAL
Intervention: Neck extension during palatoplasty
Number of subjects: 37
Study: 37541263

Group type: EXPERIMENTAL
Intervention: Surgical treatment (randomised pathway)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Non-surgical treatment (randomised pathway)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Surgical treatment (patient choice pathway)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Non-surgical treatment (patient choice pathway)
Number of subjects: 221
Study: 37541274

Group type: EXPERIMENTAL
Intervention: AI-supported screening
Number of subjects: 80033

Group type: COMPARATOR
Intervention: Standard double reading without AI
Number of subjects: 80033
Study: 37541273

Group type: EXPERIMENTAL
Intervention: Erdafitinib (8 mg/day, with potential up-titration to 9 mg/day)
Number of subjects: 217
Study: 37541600

Group type: EXPERIMENTAL
Intervention: Abstinence-Contingent Wage Supplement
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual Care Control
Number of subjects: 119
Study: 37541626

Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) assessment in ZSD patients
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Longitudinal visual acuity data
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Funduscopy findings
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Electroretinography findings
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: OCT findings in milder patients
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Systematic measures for assessing retinal dystrophy
Number of subjects: 185
Study: 37541683

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.2% 4-8 mL/hour
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single injection of ropivacaine 0.5%, 20 mL
Number of subjects: 60
Study: 37541705

Group type: EXPERIMENTAL
Intervention: Dispersible and immediate-release FDC abacavir (60 mg or 600 mg), dolutegravir (5 mg or 50 mg), and lamivudine (30 mg or 300 mg) tablets taken once per day.
Number of subjects: 57
Study: 37541706

Group type: EXPERIMENTAL
Intervention: Dynamic multilevel health system intervention including life-stage-based assessment, flexible clinic access, and rapid viral load feedback.
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: Dynamic multilevel health system intervention.
Number of subjects: 1549
Study: 37541743

Group type: EXPERIMENTAL
Intervention: Dazodalibep (DAZ)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 78
Study: 37541745

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX)
Number of subjects: 143
Study: 37541748

Group type: EXPERIMENTAL
Intervention: EnSite Precision 3D mapping system
Number of subjects: 700
Study: 37541750

Group type: EXPERIMENTAL
Intervention: Microbiota profiling in stools and saliva, microbial metabolites quantification in stools, and Treg/Th17 balance characterisation in patients with AA syndrome.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls (matched to patients with AA syndrome).
Number of subjects: 30
Study: 37541829

Group type: EXPERIMENTAL
Intervention: ADAPT+ intervention (6-session family-based health promotion program integrating mindfulness strategies)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) (1-session)
Number of subjects: 95
Study: 37541921

Group type: EXPERIMENTAL
Intervention: 3.36 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily for 30 months
Number of subjects: 241

Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Maximal exercise treadmill testing measuring METs
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Annual CAC progression
Number of subjects: 241
Study: 37541951

Group type: EXPERIMENTAL
Intervention: Ketamine (subanaesthetic doses, blood concentration of 0.2-0.3 μg ml)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ketamine (subanaesthetic doses)
Number of subjects: 14
Study: 37541984

Group type: EXPERIMENTAL
Intervention: mNGS (metagenomic next-generation sequencing) within 7 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: mNGS (metagenomic next-generation sequencing) after 7 days
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: mNGS
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional tests
Number of subjects: 101
Study: 37542140

Group type: EXPERIMENTAL
Intervention: Symptomatic rotator cuff tears
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All muscles and shoulder types
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1-kg increments in additional weights
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rotator cuff pathologies
Number of subjects: 75
Study: 37542143

Group type: EXPERIMENTAL
Intervention: Anthracycline-exposed childhood cancer survivors with cardiomyopathy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Anthracycline-exposed childhood cancer survivors without cardiomyopathy
Number of subjects: 104
Study: 37542155

Group type: COMPARATOR
Intervention: Term Reference (TR) infants, 183 subjects, assessed at 2 years of age.
Number of subjects: 1452
Study: 37542217

Group type: EXPERIMENTAL
Intervention: Subtarsal approach (Group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional transconjunctival approach (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Y-modification of the transconjunctival approach (Group C)
Number of subjects: 24
Study: 37542222

Group type: EXPERIMENTAL
Intervention: GMB/GMB group (galcanezumab 120 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: PBO/GMB group (placebo followed by galcanezumab 240 mg loading dose and then two 120 mg doses)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: GMB/GMB group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: GMB/GMB group and PBO/GMB group
Number of subjects: 96
Study: 37542234

Group type: EXPERIMENTAL
Intervention: Exercise snacking intervention (twice daily for 28 days, consisting of five muscle-strengthening exercises)
Number of subjects: 21
Study: 37542331

Group type: EXPERIMENTAL
Intervention: Breakfast Task training (5 sessions, 45 minutes each, delivered online, twice a week)
Number of subjects: 24
Study: 37542335

Group type: EXPERIMENTAL
Intervention: NuroSleeve
Number of subjects: 0
Study: 37542447

Group type: EXPERIMENTAL
Intervention: Activated Ti cages
Number of subjects: 50

Group type: COMPARATOR
Intervention: PEEK cages
Number of subjects: 50
Study: 37542470

Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) treatment initiation
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) treatment
Number of subjects: 115
Study: 37542529

Group type: EXPERIMENTAL
Intervention: Males (95 injuries, 262 injury weeks)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Females (350 injuries, 1206 injury weeks)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Higher age
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Present injury at baseline
Number of subjects: 462
Study: 37542556

Group type: EXPERIMENTAL
Intervention: Aperture fixation with biodegradable interference screws
Number of subjects: 21

Group type: COMPARATOR
Intervention: All-inside ACLR with suspensory cortical buttons
Number of subjects: 21
Study: 37542674

Group type: EXPERIMENTAL
Intervention: Mini-oral sulfate tablet (mini-OST)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional oral sulfate tablet (OST)
Number of subjects: 83
Study: 37542918

Group type: EXPERIMENTAL
Intervention: Published rocuronium PK/PD models (Wierda, Szenohradszky, Cooper, Alvarez-Gomez, McCoy)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Kleijn model
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All models
Number of subjects: 74
Study: 37542951

Group type: EXPERIMENTAL
Intervention: COPD females
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: COPD males
Number of subjects: 234

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 234